Business
Rakovina Therapeutics Announces Corporate Update Including up to $1.5 Million in New Financing, Leadership Appointments and Debt Restructuring
Proposed $1.0 million Convertible Debenture and concurrent $500,000 Private Placement Intended to Support Near-Term Operations Board and Management Enhancements Strengthen Governance and Capital Markets Execution Current Convertible Debenture Maturity Extended; Further Debt Optimization Planned VANCOUVER, British Columbia, Jan. 27, 2026 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (TSX-V: RKV; FSE: 7JO0) (“Rakovina” or the “Company”), a biopharmaceutical company advancing novel cancer therapie
About this update from Rakovina Therapeutics Inc
[{"type":"image","alt":"Rakovina Therapeutics Inc","displaySize":"","headline":null,"caption":"Rakovina Therapeutics Inc","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":101,"url":"https://media.zenfs.com/en/globenewswire.com/5f38052c45a7c766c8843075311b5e6b"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/8pDE_lHFFxIFLy74uLNlBg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTE0MTtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/5f38052c45a7c766c8843075311b5e6b","width":300,"height":101}},"lazy":false},{"type":"table","headerItems":[],"items":[{"val":[{"style":"max-width:100%;width:100%;min-width:100%;text-align:center;vertical-align:middle;padding-left:0;padding-right:0;vertical-align:bottom;","val":[{"type":"text","content":"Proposed $1.0 million Convertible Debenture and concurrent $500,000 Private Placement Intended to Support Near-Term Operations","length":126,"tagName":"p","attribs":{}}]}]},{"val":[{"style":"text-align:center;vertical-align:middle;padding-left:0;padding-right:0;vertical-align:bottom;","val":[{"type":"text","content":" ","length":6,"tagName":"p","attribs":{}}]}]},{"val":[{"style":"text-align:center;vertical-align:middle;padding-left:0;padding-right:0;vertical-align:bottom;","val":[{"type":"text","content":"Board and Management Enhancements Strengthen Governance and Capital Markets Execution","length":85,"tagName":"p","attribs":{}}]}]},{"val":[{"style":"text-align:center;vertical-align:middle;padding-left:0;padding-right:0;vertical-align:bottom;","val":[{"type":"text","content":" ","length":6,"tagName":"p","attribs":{}}]}]},{"val":[{"style":"text-align:center;vertical-align:middle;padding-left:0;padding-right:0;vertical-align:bottom;","val":[{"type":"text","content":"Current Convertible Debenture Maturity Extended; Further Debt Optimization Planned","length":82,"tagName":"p","attribs":{}}]}]},{"val":[{"style":"text-align:center;vertical-align:middle;padding-left:0;padding-right:0;vertical-align:bottom;","val":[{"type":"text","content":" ","length":6,"tagName":"p","attribs":{}}]}]}],"length":305},{"type":"text","content":"VANCOUVER, British Columbia, Jan. 27, 2026 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (TSX-V: RKV; FSE: 7JO0) (“Rakovina” or the “Company”), a biopharmaceutical company advancing novel cancer therapies, today provides a comprehensive corporate update addressing nea...